De-Risking Life Sciences Investments

In life sciences, scientific rigor is essential. But it is not sufficient.

Across therapeutic areas and product categories, a significant percentage of approved products fail to meet their commercial expectations. This is rarely because the science is flawed. More often, it reflects a different kind of risk — adoption risk — that is not fully understood until late in development, when strategic flexibility has already narrowed.

Understanding and addressing this risk earlier can materially improve both development outcomes and investment performance.

The Gap Between Scientific Success and Commercial Reality

The industry has developed strong frameworks for evaluating clinical and regulatory risk. Trial design, statistical endpoints, safety thresholds, and regulatory pathways are scrutinized in detail.

Yet the factors that ultimately determine commercial performance — physician behavior, payer confidence, stakeholder incentives, workflow integration, and perceived value — are often addressed later or assumed to resolve after approval.

This creates a structural gap.

A product may achieve regulatory success while still facing uncertainty around differentiation, access, and real-world fit. When these dynamics are not anticipated early, commercial performance can fall short of forecasts, affecting revenue trajectory, capital efficiency, and long-term valuation.

In today’s environment of increasing development costs and heightened stakeholder scrutiny, this gap has become increasingly consequential.

Understanding Adoption Risk

Adoption risk reflects uncertainty around how a product will perform once it enters real-world clinical and economic environments.

It encompasses questions such as:

• Will physicians perceive the product as meaningfully differentiated?

• Will payers view the value proposition as compelling enough to support access?

• Will the product integrate seamlessly into clinical workflow?

• Will stakeholders have confidence in the evidence and its relevance?

Unlike clinical risk, adoption risk is shaped not only by data but by human behavior, incentives, and context.

Programs that understand these dynamics earlier retain greater flexibility to strengthen positioning, clarify value, and reduce friction before major capital commitments are finalized.

Why Timing Changes Outcomes

Strategic flexibility is greatest early in development and narrows over time.

Decisions made during early clinical planning — including comparator selection, endpoint choice, and target population definition — often shape how a product will ultimately be positioned and perceived.

When commercial implications are considered only after these decisions are locked, options become limited. Conversely, when adoption dynamics are evaluated early, organizations can:

• Strengthen differentiation credibility

• Align evidence with stakeholder expectations

• Anticipate barriers before launch

• Improve forecasting reliability

• Enhance capital allocation decisions

The timing of commercial clarity can materially influence long-term outcomes.

Implications for Investors and Development Teams

For investors, early commercial insight improves portfolio decisions. It helps distinguish between scientific promise and real commercial potential, reducing the risk of capital inefficiency.

For development teams, integrating commercial perspective earlier enhances strategic alignment and reduces downstream surprises. Rather than reacting to adoption challenges post-approval, teams can proactively design for real-world success.

This approach does not diminish scientific rigor. It complements it.

Regulatory approval is necessary. Sustainable commercial adoption is what ultimately creates value.

Designing for Real-World Success

Programs that consistently perform well share a common characteristic: they anticipate stakeholder behavior early and design accordingly.

They seek clarity not only on whether a product can be approved, but whether it will be adopted — and why.

This requires:

• Viewing development through both scientific and commercial lenses

• Evaluating differentiation in the context of real-world decision making

• Continuously assessing stakeholder perception

• Aligning clinical evidence with value expectations

By addressing adoption risk early, organizations improve the likelihood that strong science translates into meaningful commercial impact.

Continuing the Conversation

The relationship between scientific success and commercial performance continues to evolve. As development costs rise and stakeholder expectations shift, early commercial clarity becomes increasingly central to long-term value creation.

If these themes resonate with what your organization is evaluating, we welcome the opportunity to exchange perspectives.